Skip to Content

Posts tagged with "Pharmacokinetics"

  • Drug Development

    Sticky Containers, Vanishing Drugs

    There’s no end to the variables that can kick your data around in drug discovery. If you concentrate completely on all the things that could go wrong, though, you’ll be too terrified to run any useful experiments. You have to push on, but stay alert. It’s like medical practice: most of the time you don’t… Read More
  • Academia (vs. Industry)

    Getting To Lyrica

    There’s an interesting article in Angewandte Chemie by Richard Silverman of Northwestern, on the discovery of Lyrica (pregabalin). It’s a rare example of a compound that came right out of academia to become a drug, but the rest of its story is both unusual and (in an odd way) typical. The drug is a very… Read More
  • Animal Testing

    The Animal Testing Hierarchy

    I’ve had some questions about animal models and testing, so I thought I’d go over the general picture. As far as I can tell, my experience has been pretty representative. There are plenty of animal models used in my line of work, but some of them you see more than others. Mice and rats are… Read More
  • Diabetes and Obesity

    Eat It, Breath It, Soak in It?

    After Pfizer’s Exubera inhaled-insulin product died so horribly in the market last year, the other companies working in the same space had to be worried. Lilly and Alkermes have had a long-running program, as has a smaller company called Mannkind. But recently, another contender, Novo Nordisk, has announced that they and partner Aradigm have deci… Read More
  • Drug Development

    Like Clockwork

    There are a lot of drug development issues that people outside the field (and beginning medicinal chemists) don’t think about. A significant one that sounds trivial is how often your wonder drug is going to be taken. Once a day is the standard, and it’s generally what we shoot for unless there’s some reason to… Read More
  • Life in the Drug Labs

    Sulfur, Your Pal. Mostly.

    I had a question the other day in my e-mail about various sulfur-containing functional groups in drugs. My answers, condensed, were as follows: Sulfides: will always be under suspicion for oxidation in vivo. If that’s your main mode of metabolism and clearance, though, then the problem can be manageable. Still, many people avoid them to… Read More
  • Cardiovascular Disease

    Bigger And Greasier

    Several people have remarked on how large and greasy a molecule torcetrapib is, and speculated about whether that could have been one of its problems. Now, I have as much dislike of large and greasy molecules as any good medicinal chemist, but somehow I don’t think that was the problem here. For the non-medicinal-chemists, the… Read More
  • Cancer

    Clay Lies Still, But Blood’s A Rover

    When a drug makes it into the bloodstream (which is no sure thing, on my side of the business), it doesn’t just float around by itself. Blood itself is full of all kinds of stuff, and there are many things in it that can interact with drug molecules. For one thing, compounds can actually wander… Read More
  • Drug Development

    Down the Hatch

    We have a lot of received wisdom in the drug business, rules of thumb and things that everybody knows. One of the things that we all know is that the gut wall isn’t much fun for our drugs to get across sometimes. That’s inconvenient, since most people would prefer to swallow their medicine rather than… Read More
  • Drug Development

    The March of Folly Leader Board

    The first comment to the original March of Folly post below mirrors the e-mail I’ve received: the people’s choice for the technology most-likely-to-be-embarrassing is. . .(rustling of envelope): RNA interference. There’s a good case to be made for that, and it doesn’t contradict my oft-stated opinion that RNAi is going to be… Read More